Is rituximab an imported drug or a domestic drug? Why is it so expensive?

Rituximab is a lymphoma drug developed by Roche, and its full name is F. Hoffmann-La Roche, Ltd., which is a multinational drug research and development manufacturer headquartered in Basel, Switzerland. Founded in 1896, it now belongs to Roche Holdings Limited. Relatively speaking, imported drugs have better purity and more reliable data in all aspects, but the price is still higher than that of domestic drugs. Rituximab is a good drug, but ordinary families cannot afford it. There is no original research in China, but it is highly imitative. The import price is part of the patent fee, and the good drugs from domestic manufacturers are also good. Don't be superstitious, as long as the result is ok, I wish you a speedy recovery! Selection of chemotherapy drugs: Imported or domestic chemotherapy is one of the most important treatment methods for tumors. Among all kinds of chemotherapy drugs, how to choose one with high curative effect, few side effects and economic benefits is a concern of both doctors and patients. For a certain drug, whether it is imported or made in China often makes many cancer patients and their families hesitate. Where are the imported drugs expensive? Imported drugs are expensive because of high research and development costs, complex manufacturing processes and high prices. In addition, the state imposes tariffs on imported drugs and carries out macro-control on the import quantity. The packaging of foreign drugs is generally more particular, and the cost will definitely increase. Communication and analysis: Reasonable selection of many new chemotherapy drugs (such as paclitaxel, taxotere, gemcitabine, vinorelbine, platinum oxalate, etc.) in 1990s. ) went on the market, which greatly improved the curative effect, reduced the side effects and opened a new chapter in tumor chemotherapy. But these drugs are developed by developed countries such as Europe and America. When they first entered the China market, the prices were quite high, and most cancer patients could only flinch. However, similar drugs in China were listed one after another soon, and the price was greatly reduced, which was acceptable to most people. At the end of 1990s, the appearance of molecular targeted drugs (such as Gleevec for chronic myeloid leukemia, Herceptin for breast cancer and Rituximab for lymphoma) brought hope to many patients with advanced and recurrent tumors. However, due to the lack of similar drugs in China, it is still "sky-high" for many patients. Choosing imported drugs or domestic drugs is nothing more than three issues: economic strength, curative effect and side effects. Patients with strong economic strength generally prefer imported drugs. The working class and ordinary people often hesitate on this issue. Although there is no clear data to prove the advantages and disadvantages of the two drugs, from the clinical observation, domestic chemotherapy drugs are almost the same as similar imported drugs in terms of efficacy, tolerance and side effects. Tumor treatment is a long and expensive process. Many patients and their families were willing to spend money at the beginning of diagnosis, using more imported drugs, and later stopped treatment because the money was used up. As cancer patients and their families, they should consider from many aspects, including their own economic strength, pathological types, stages and differentiation of tumors, patients' physique and tolerance. In-depth communication with the competent doctor, through comprehensive analysis, make the final choice.